Journey Medical CORP 8-K Filing

Ticker: DERM · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1867066

Sentiment: neutral

Filing Stats: 1,354 words · 5 min read · ~5 pages · Grade level 16.9 · Accepted 2025-02-05 16:01:44

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On February 5, 2025, Journey Medical Corporation (the " Journey Medical ") announced that it expects to report that it had $20.3 million in cash and cash equivalents as of December 31, 2024. Additionally, Journey Medical is reaffirming its previously issued guidance for the full year ended December 31, 2024 of: $55 to $60 million in net product revenue; selling, general and administrative expense in the range of $39 to $42 million; and research and development expense in the range of $8 to $10 million. These estimates are based on information currently available to management. Journey Medical's actual results are not expected to vary materially from the estimated preliminary results included herein. The estimates included in this Current Report on Form 8-K have been prepared by, and are the responsibility of management, and Journey Medical's independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures with respect to the estimates and does not express an opinion or any other form of assurances with respect thereto. The information in this Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On February 5, 2025, Journey Medical will be hosting a conference call to provide an update on the commercial launch plan for the Company's recently approved dermatological product, Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29. A copy of the slide presentation that Journey Medical will present during this call is attached to this Current Report on Form 8-K as Exhibit 99.1.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished herewith: Exhibit Number Description 99.1 Investor Presentation, dated February 5, 2025. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K may contain "forward-looking Act of 1934, as amended. As used below and throughout this Current Report on Form 8-K, the words "the Company", "we", "us" and "our" may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words "anticipate," "believe," "estimate," "may," "expect," "will," "could," "project," "intend," "potential" and similar expressions are generally intended to identify forward-looking statements. Forward-looking our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products' commercial opportunity and profitability, in

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Journey Medical Corporation (Registrant) By: /s/ Claude Maraoui Claude Maraoui Chief Executive Officer, President and Director Date: February 5, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing